OakChart

Faeth Therapeutics Inc

FTHHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

13.35+0.43 (3.33%)
2026-11-11 23:44 CET
Market cap
333.90 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-211.36 USD m
Free cash flow, TTM
-43.28 USD m
EPS diluted, TTM
-138.82
P/E
-
Compare

Price

FTH against its 20, 50 and 200-day averages
2050200beatmissearnings
10.0020.0030.0040.002.0M4.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26FTHclose 13.3520-day 18.4950-day 26.22200-day 25.4213.3552w high

68.3% under the 52-week high of 42.14 on 8 Sep 2026. 52-week low 7.45 on 5 Dec 2025. Last 15 sessions, 111.0% high to low

Volume 3.07× normal · the line is the 50-bar volume average

Profile

FTH
52-week range, 17% of the way up
7.4542.14

Faeth Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Austin, TX.

Employees29
IPOFeb 04, 2021
Beta-0.13
ATR, 14d2.71
Rel volume3.07
Short float14.84%
Insider own28.82%
Inst own50.60%

Snapshot

6 groups

Valuation

Index-
Market Cap345.01M
Enterprise Value177.13M
Income-211.36M
Sales0.00M
Book/sh6.23
Cash/sh6.76
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees29
IPOFeb 04, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.14
P/C1.97
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio16.12
Current Ratio16.12
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-138.82
EPS next Y-3.55
EPS next Q-0.85
EPS this Y8.80%
EPS next Y76.74%
EPS next 5Y40.06%
EPS past 3/5Y19.15% -4.83%
Sales past 3/5Y- -
EPS Y/Y TTM-624.45%
Sales Y/Y TTM-
EPS Q/Q78.21%
Sales Q/Q-
EarningsNov 03 BMO
EPS/Sales Surpr.-1.07% -

Ownership

Insider Own28.82%
Insider Trans0.32%
Inst Own50.60%
Inst Trans59.10%
ROA-204.67%
ROE-221.47%
ROIC-125.91%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-27.79%
SMA50-49.08%
SMA200-47.49%
Trades-

Technical

Shs Outstand25.84M
Shs Float18.40M
Short Float14.84%
Short Ratio6.14
Short Interest2.73M
52W High42.14 -68.32%
52W Low7.45 79.19%
Volatility20.77% 13.45%
ATR (14)2.71
RSI (14)30.92
Beta-0.13
Rel Volume3.07
Avg Volume444.44K
Volume1,362,575

Performance

Perf Week-33.22%
Perf Month-37.94%
Perf Quarter-53.24%
Perf Half Y-36.67%
Perf YTD25.12%
Perf Year39.57%
Perf 3Y-7.29%
Perf 5Y-92.29%
Perf 10Y-
Recom1.12
Target Price57.07
Prev Close12.92
Price13.35
Change %3.33%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 16, 2026InitiatedWWilliam BlairOutperform
Sep 16, 2026InitiatedGGuggenheimBuy$70+424.3%
Sep 09, 2026InitiatedTTD CowenBuy
Aug 21, 2026InitiatedNNeedhamBuy$56+319.5%
Jul 31, 2026InitiatedRRaymond JamesOutperform$56+319.5%
Jul 28, 2026InitiatedOOppenheimerOutperform$60+349.4%
Jul 20, 2026InitiatedCCitizensMkt Outperform$51+282.0%
Jun 26, 2026InitiatedRRobert W. BairdOutperform$57+327.0%
Jun 22, 2026InitiatedHH.C. WainwrightBuy$60+349.4%
Jun 11, 2026InitiatedBBTIG ResearchBuy$55+312.0%

Peers

Mkt cap
TickerCompanyMkt cap
CELCCelcuity Inc3.16B
RLAYRelay Therapeutics Inc4.36B
BBOTBridgeBio Oncology Therapeutics Inc205.24M
OLMAOlema Pharmaceuticals Inc703.48M
ARVNArvinas Inc452.51M
KURAKura Oncology Inc687.66M
IDYAIdeaya Biosciences Inc3.16B
TNGXTango Therapeutics Inc4.36B
ATOSAtossa Therapeutics Inc20.26M
CNTXContext Therapeutics Inc19.85M

Insider trading

latest 14 of 44
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Cambrian BioPharma Inc10% OwnerJul 22 '26Proposed Sale27.99130,1423,642,675Aug 11 12:52 PM
STEPHENSON BRIAN CChief Financial OfficerJun 30 '26Buy24.257,803189,24041,688Jul 01 08:09 PM
STEPHENSON BRIAN CChief Financial OfficerJul 01 '26Buy23.505,000117,49246,688Jul 01 08:09 PM
STEPHENSON BRIAN CChief Financial OfficerJun 29 '26Buy23.3483119,39633,885Jul 01 08:09 PM
STEPHENSON BRIAN CChief Financial OfficerJun 24 '26Buy26.139,391245,36026,804Jun 26 07:40 PM
STEPHENSON BRIAN CChief Financial OfficerJun 26 '26Buy24.956,250155,90833,054Jun 26 07:40 PM
STEPHENSON BRIAN CChief Financial OfficerJun 23 '26Buy24.369,230224,80617,413Jun 24 06:58 PM
STEPHENSON BRIAN CChief Financial OfficerJun 22 '26Buy22.138,183181,1158,183Jun 24 06:58 PM
Parikh Anand KiranPresident and CEOJun 22 '26Option Exercise1.1653,46562,019817,699Jun 24 06:55 PM
Parikh Anand KiranPresident and CEOJun 22 '26Buy19.762,80655,447764,234Jun 24 06:55 PM
Cambrian BioPharma Inc10% OwnerJun 01 '26Sale20.0225,000500,543130,142Jun 01 05:21 PM
Peyer James10% OwnerJun 01 '26Sale20.0225,000500,543130,142Jun 01 05:20 PM
MILLENNIUM MANAGEMENT LLC10% OwnerApr 02 '26Buy35.012,00370,133144,974May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC10% OwnerApr 07 '26Buy33.381,10836,985133,986May 15 04:24 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWCiShares Micro-Cap ETFAUM: 1.22B
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 95.28B
SCHBSchwab U.S. Broad Market ETFAUM: 44.09B
ONEQFidelity Nasdaq Composite Index ETFAUM: 10.35B
LABUDirexion Daily S&P Biotech Bull 3X ETFAUM: 583.37M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 100

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-03-0.790-0.782-0.7900.000.0016
2026Q22026-08-04-2.840-2.636-2.8370.000.0010
2026Q12026-05-15-131.45-0.620-131.450.000.001
2025Q42026-03-30-3.790--3.7390.00--
2025Q32025-11-14-3.620-4.110-3.6230.000.001
2025Q22025-08-05-3.910-5.600-3.9150.000.002
2025Q12025-05-06-5.400-4.467-5.4490.00-3
2024Q42025-03-28-6.200-5.666-6.1750.000.003
2024Q32024-11-14-5.800-6.236-5.7680.000.004
2024Q22024-08-06-5.600-5.770-5.6900.000.004
2024Q12024-05-09-6.400-5.500-6.3810.000.003
2023Q42024-02-28-6.000-6.152-5.9240.000.003
2023Q32023-11-07-5.600-6.782-5.5840.00-2
2023Q22023-08-03-6.200-6.610-6.153--2
2023Q12023-05-09-6.600-7.116-6.594-0.002
2022Q42023-03-28-7.982-8.002-7.9580.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-250.62-39.144-13.2100.000.00
2021FY-26.600-26.466-26.5560.000.00
2022FY-31.600-31.582-31.6500.000.00
2023FY-24.400-24.598-24.3990.000.00
2024FY-24.000-23.467-24.0130.000.00
2025FY-16.720--16.7200.00-
2026FY--15.248--0.00
2027FY--3.546--0.00
2028FY--3.601--0.00
2029FY--3.708--6.98
2030FY--3.120--42.18

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0312000.000.000.00
2026Q4S2026-09-1412000.000.000.00
2026Q4S2026-09-1111000.000.000.00
2026Q4S2026-09-0810000.000.000.00
2026Q4S2026-08-279000.000.000.00
2026Q4S2026-08-0710000.000.000.00
2026Q4S2026-08-049000.000.000.00
2026Q4S2026-08-039000.000.000.00
2026Q4S2026-07-308000.000.000.00
2026Q4S2026-07-247000.000.000.00
2026Q4S2026-07-176000.000.000.00
2026Q4S2026-06-195000.000.000.00
2026Q4S2026-06-104000.000.000.00
2026Q4S2026-05-283000.000.000.00

Estimate history

EPS, annual-11.487-14.011-13.21-26.556-31.65-24.399-24.013-16.724-138.8162
Period20182019202020212022202320242025TTM
EPS, quarterly-5.768-6.175-5.449-3.915-3.623-3.739-131.451-2.837-0.789
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual1.4661.4661.5291.531.5381.2521.2591.26225.842
Period20182019202020212022202320242025MRQ
Shares, quarterly1.2581.2591.261.2611.2611.2621.3425.83325.842
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.110.140.550.571.810.690.210.070.04
Gross Profit-0.11-0.14-0.55-0.57-1.81-0.69-0.21-0.07-0.04
Selling, General and Administrative Excl. Other74.2922.1531.1136.4947.3136.8019.2412.3612.70
Research and Development41.0410.9618.6318.3029.5821.6611.928.358.23
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-74.40-22.29-31.66-37.06-49.12-37.48-19.45-12.44-12.74
Interest Expense-0.030.090.140.220.671.692.260.33
Unusual Expense141.660.000.950.001.07-0.57-1.042.050.00
Net Income Before Taxes-211.36-21.09-30.16-34.10-48.59-36.79-20.10-16.74-13.04
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-211.36-21.09-30.16-34.10-48.59-36.79-20.10-16.74-13.04
Net Income From Continuing Operations-211.36-21.09-30.16-34.10-48.59-36.79-20.10-16.74-13.04
Net Income-211.36-21.09-30.16-34.10-48.59-36.79-20.20-20.54-16.84
EPS (Recurring)-4.34-16.72-23.48-24.40-31.16-26.84-13.69-13.03-11.49
EPS (Basic, Before Extraordinaries)-138.82-16.72-24.01-24.40-31.65-26.56-13.21-14.01-11.49
EPS (Diluted)-138.82-16.72-24.01-24.40-31.65-26.56-13.21-14.01-11.49
EBITDA-74.29-22.15-31.11-36.49-47.31-36.80-19.24-12.36-12.70
Non-Operating Income (Expense)4.701.242.553.111.820.790.00-0.000.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense26.201.273.134.455.815.661.491.191.18
Shares Outstanding25.841.261.261.251.541.531.531.471.47
Market Capitalization333.90333.9012.3417.3045.77177.53170.38--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.020.030.030.030.030.040.030.14
Gross Profit-0.02-0.03-0.03-0.03-0.03-0.04-0.03-0.14
Selling, General and Administrative Excl. Other22.0718.3628.944.924.825.177.247.18
Research and Development11.749.1817.962.172.542.533.734.49
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-22.09-18.39-28.97-4.96-4.85-5.21-7.27-7.32
Interest Expense--0.000.000.010.010.010.02
Unusual Expense0.000.00141.660.000.000.000.000.95
Net Income Before Taxes-20.40-16.01-170.24-4.72-4.57-4.94-6.86-7.77
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-20.40-16.01-170.24-4.72-4.57-4.94-6.86-7.77
Net Income From Continuing Operations-20.40-16.01-170.24-4.72-4.57-4.94-6.86-7.77
Net Income-20.40-16.01-170.24-4.72-4.57-4.94-6.86-7.77
EPS (Recurring)-0.79-2.84-54.88-3.74-3.62-3.91-5.45-5.65
EPS (Basic, Before Extraordinaries)-0.79-2.84-131.45-3.74-3.62-3.91-5.45-6.18
EPS (Diluted)-0.79-2.84-131.45-3.74-3.62-3.91-5.45-6.18
EBITDA-22.07-18.36-28.94-4.92-4.82-5.17-7.24-7.18
Non-Operating Income (Expense)1.692.380.390.240.290.280.420.52
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.524.4812.900.290.250.260.460.39
Shares Outstanding25.8425.831.341.261.261.261.261.26
Market Capitalization333.90644.4739.7613.4611.9210.819.9312.34

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments21.1841.3465.76107.12147.6216.600.250.65
Short Term Receivables0.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets0.320.591.491.470.921.380.250.63
Total Current Assets21.5141.9367.25108.59148.5417.970.501.28
Net Property, Plant & Equipment1.383.387.049.724.641.270.270.12
Total Investments and Advances0.000.000.000.000.000.000.000.00
Intangible Assets-----0.000.000.00
Deferred Tax Assets0.340.85------
Other Assets0.020.050.090.060.042.190.450.45
Total Assets23.2446.2174.37118.38153.2221.431.221.85
Short Term Debt Incl. Current Port. of LT Debt1.452.322.442.130.680.0016.050.70
Accounts Payable0.691.251.694.472.463.883.451.11
Other Current Liabilities2.111.881.512.461.750.952.210.86
Total Current Liabilities4.255.455.649.074.894.8321.712.66
Long Term Debt0.061.533.775.901.670.570.004.05
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.340.85------
Other Liabilities0.000.000.070.000.150.140.621.07
Total Liabilities4.657.829.4814.976.715.5422.337.79
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.0072.3447.5547.55
Common Equity18.5938.3964.89103.41146.51-56.44-68.66-53.48
Total Shareholders Equity18.5938.3964.89103.41146.5115.89-21.12-5.93
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity18.5938.3964.89103.41146.5115.89-21.12-5.93
Total Liabilities & Stockholders Equity23.2446.2174.37118.38153.2221.431.221.85
Book Value Per Share14.7430.4951.8567.2395.73-36.90-46.83-36.47
Tangible Book Value Per Share14.7430.4951.8567.2395.73-36.90-46.83-36.47
Full-Time Employees29152728----
Price to Book Ratio2.070.320.240.401.211.10--
Return on Assets-60.72-50.02-35.38-35.78-42.13-177.52-1,091.62-
Return on Equity-74.01-58.40-40.52-38.88-45.31---
Return on Invested Capital-113.05-75.56-49.66-44.45-24.83-122.11--
Quick Ratio5.067.7011.9211.9830.383.720.020.48
Current Ratio5.067.7011.9211.9830.383.720.020.48

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-211.36-21.09-30.16-34.10-48.59-36.79-20.10-16.74-13.04
Depreciation0.110.140.550.571.810.690.210.070.04
Other Funds (Non Cash)158.172.085.425.846.755.732.584.631.19
Funds from Operations-53.08-18.86-24.18-27.69-40.03-30.38-17.31-12.04-11.80
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital9.81-1.59-0.49-4.331.010.12-0.403.471.49
Cash from Operating Activities-43.27-20.45-24.67-32.02-39.03-30.26-17.70-8.57-10.31
Capital Expenditures-0.01-0.02-0.15-0.18-0.32-2.03-1.21-0.05-0.03
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses6.460.250.000.170.010.320.000.000.00
Purchase or Sale of Investments-143.7019.5422.5938.4350.26-141.410.000.000.00
Purchase of Investments-241.90-25.16-44.59-21.15-46.87-183.670.000.000.00
Sale Or Maturity of Investments98.2044.6967.1859.5897.1242.260.000.000.00
Other Uses0.000.000.000.000.000.00-0.200.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-137.2519.7722.4438.4149.95-143.12-1.40-0.05-0.03
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock184.330.010.03-10.340.34164.1237.030.150.00
Repurchase of Common Pref Stock0.000.000.00-10.380.000.000.000.000.00
Sale of Common Pref Stock184.330.010.030.050.34164.1237.030.150.00
Proceedsfrom Stock Options183.090.010.030.050.10164.0937.010.000.00
Issuance or Reduction of Debt, Net-0.19-0.79-0.81-0.76-0.63-0.260.538.070.75
Change in Long Term Debt-0.19-0.79-0.81-0.76-0.63-0.260.538.070.75
Issuance of Long Term Debt0.000.000.000.000.000.000.578.100.75
Reduction of Long Term Debt-0.19-0.79-0.81-0.76-0.63-0.26-0.04-0.030.00
Net Financing Active Other Cash Flow0.000.14-0.01-0.080.000.08-2.100.000.00
Other Financing Activities Uses0.00-0.00-0.01-0.080.000.00-2.100.000.00
Cash from Financing Activities184.14-0.65-0.79-11.17-0.29163.9435.458.220.75
Net Change in Cash3.62-1.33-3.02-4.7810.64-9.4416.34-0.40-9.59
Free Cash Flow-43.28-20.47-24.82-32.20-39.35-32.28-18.91-8.62-10.34
Preferred Dividends (Cash Flow)-0.000.000.000.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments174.79186.44202.7921.1825.0428.63
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets3.052.221.440.320.740.94
Total Current Assets177.84188.66204.2321.5125.7929.57
Net Property, Plant & Equipment0.130.570.981.381.792.19
Total Investments and Advances0.000.000.000.000.000.00
Deferred Tax Assets---0.34--
Other Assets0.980.080.170.020.020.02
Total Assets178.95189.31205.3823.2427.5931.78
Short Term Debt Incl. Current Port. of LT Debt0.140.591.041.451.881.96
Accounts Payable2.992.153.420.690.310.35
Other Current Liabilities7.906.849.732.112.251.56
Total Current Liabilities11.039.5814.194.254.443.87
Long Term Debt0.000.000.000.060.150.60
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.34--
Other Liabilities0.050.000.000.000.000.00
Total Liabilities11.099.5814.194.654.584.47
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value6.776.77328.480.000.000.00
Common Equity161.10172.96-137.2918.5923.0127.31
Total Shareholders Equity167.86179.72191.1918.5923.0127.31
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity167.86179.72191.1918.5923.0127.31
Total Liabilities & Stockholders Equity178.95189.31205.3823.2427.5931.78
Book Value Per Share6.236.70-102.4314.7418.2421.66
Tangible Book Value Per Share6.236.70-102.4314.7418.2421.66
Full-Time Employees---29--
Price to Book Ratio2.07-0.241.460.490.440.34
Return on Assets-204.67-176.88-151.41-60.72-59.72-58.58
Return on Equity-221.47-188.88-165.30-74.01-70.19-67.47
Return on Invested Capital-12.15-8.91-89.04-25.29-19.73-17.69
Quick Ratio16.1219.6914.395.065.817.64
Current Ratio16.1219.6914.395.065.817.64

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-20.40-16.01-170.24-4.72-4.57-4.94
Depreciation0.020.030.030.030.030.04
Other Funds (Non Cash)7.663.83146.150.530.480.47
Funds from Operations-12.72-12.15-24.05-4.15-4.05-4.42
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.28-3.5213.320.290.47-1.49
Cash from Operating Activities-13.00-15.67-10.73-3.86-3.59-5.91
Capital Expenditures-0.000.00-0.010.000.00-0.02
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.006.460.000.000.21
Purchase or Sale of Investments0.18-108.07-37.892.081.748.56
Purchase of Investments-76.82-114.67-43.89-6.52-9.85-2.44
Sale Or Maturity of Investments77.006.606.008.6011.5911.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.17-108.07-31.442.081.748.76
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.10-1.67185.890.000.000.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.10-1.67185.890.000.000.01
Proceedsfrom Stock Options-1.13-1.67185.890.000.000.01
Issuance or Reduction of Debt, Net0.00-0.02-0.06-0.11-0.15-0.31
Change in Long Term Debt0.00-0.02-0.06-0.11-0.15-0.31
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.00-0.02-0.06-0.11-0.15-0.31
Net Financing Active Other Cash Flow0.000.000.000.000.000.14
Other Financing Activities Uses0.000.000.000.000.00-0.00
Cash from Financing Activities0.10-1.68185.83-0.11-0.15-0.17
Net Change in Cash-12.72-125.42143.66-1.89-2.002.68
Free Cash Flow-13.01-15.67-10.74-3.86-3.59-5.92

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3014.84%2.7M18.4M372.44K
2026-10-1512.62%2.3M18.4M348.27K
2026-09-3011.24%2.1M18.4M338.76K
2026-09-157.17%1.3M18.4M262.12K
2026-08-315.96%1.1M18.4M222.14K
2026-08-144.49%0.8M18.4M178.60K
2026-07-314.38%0.8M18.6M134.60K
2026-07-154.20%0.9M21.2M85.78K
2026-06-303.68%0.8M21.2M55.52K
2026-05-29319.31%0.8M0.3M62.08K
2026-05-15370.70%0.8M0.2M289.85K
2026-04-3091.69%0.8M0.9M296.29K
2026-04-1594.05%0.9M0.9M309.54K
2026-03-3194.89%0.9M0.9M321.96K
2026-03-1383.24%0.7M0.9M310.54K
2026-02-2762.63%0.5M0.9M318.32K
2026-02-133.02%0.0M0.9M85.55K
2026-01-303.03%0.0M0.9M82.75K
2026-01-153.36%0.0M0.9M89.44K
2025-12-313.02%0.0M0.9M72.49K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call5.007.5011.000.0013.1610.000.000.922-0.1310.003
call10.002.506.004.205.9043.002.000.796-0.1080.006
call15.000.002.452.453.6950.001.000.534-0.1730.008
call20.000.004.900.004.8820.000.000.457-0.2340.009
call25.000.004.900.005.8210.000.000.420-0.2750.008
call30.000.004.900.006.5150.000.000.399-0.3030.008
put5.000.004.900.007.7000.000.00-0.074-0.1300.003
put10.000.001.000.002.92221.000.00-0.219-0.0930.006
put15.000.004.901.804.8661.001.00-0.454-0.1660.009
put20.004.508.000.003.7760.000.00-0.543-0.2370.008
put25.009.5014.000.005.9590.000.00-0.577-0.2760.008
put30.0014.5019.000.006.6530.000.00-0.597-0.3040.008

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-09SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-11-03S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-11-038-KCurrent report2026-11-03SEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-23SEC
2026-10-273Initial statement of beneficial ownership of securities2026-10-23SEC
2026-10-278-KCurrent report2026-10-23SEC
2026-09-178-KCurrent report2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-153Initial statement of beneficial ownership of securities2026-09-11SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-283Initial statement of beneficial ownership of securities2026-06-15SEC
2026-07-234Statement of changes in beneficial ownership of securities2026-07-21SEC
2026-07-234Statement of changes in beneficial ownership of securities2026-07-21SEC
2026-07-238-KCurrent report2026-07-21SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-233Initial statement of beneficial ownership of securities2026-06-13SEC
2026-06-23SCHEDULE 13GSEC
2026-06-23SCHEDULE 13GSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-07117.49K100
2026-061.07M71.00M2
2026-050000
2026-04354.34K4574.51K4
2026-03987.38K4129.94K4
2026-020000
2026-010000
2025-1200574.53K7
2025-110000

Institutional holders

Manager% owned
MONTANOVA CAPITAL, LLC7.84%
Avoro Capital Advisors LLC5.60%
BAKER BROS. ADVISORS LP4.99%
BALYASNY ASSET MANAGEMENT L.P.4.04%
RA CAPITAL MANAGEMENT, L.P.2.80%
Vivo Capital, LLC2.80%
Logos Global Management LP2.80%
Fairmount Funds Management LLC2.80%
Caligan Partners LP2.44%
B Group, Inc.2.37%

Funds

Fund% owned
Franklin Biotechnology Discovery Fund0.70%
VANGUARD EXTENDED MARKET INDEX FUND0.04%
Fidelity Nasdaq Composite Index Fund0.02%
Fidelity Extended Market Index Fund0.02%
iShares Micro-Cap ETF0.01%
Fidelity Total Market Index Fund0.01%
Fidelity Series Total Market Index Fund0.00%
1290 VT Micro Cap Portfolio0.00%
Guggenheim Active Allocation Fund0.00%

OakChart. FTH. Cached 15 minutes.